Andelyn Biosciences    

http://www.andelynbio.com

Andelyn Biosciences invites you to visit us at Booth 148.

Andelyn Biosciences (https://www.andelynbio.com/) is pioneering solutions that turn hope into reality as a cell and gene therapy CDMO. Capabilities span viral vector process and analytical development, small to large scale adherent and suspension based GMP manufacturing up to 2000L. Having 20+ years of experience with viral vector manufacturing, Andelyn offers access to globally recognized thought leaders with troubleshooting/characterization expertise and GMP material produced for 75+ worldwide clinical trials. In addition to producing 400+ cGMP clinical batches, Andelyn provides research and tox grade plasmids with an additional offering of GMP plasmid manufacturing, full quality system/regulatory support and supply chain vertical integration. Its state-of-the-art 185,000 sq ft commercial manufacturing facility will expand capacity across 8+ production suites for customization of new programs and a tech transfer program, offering clinical through commercial-scale capabilities that will help accelerate innovative therapies to bring more treatments to more patients. Gene and cell therapy, AAV viral vector manufacturing, Plasmid Manufacturing, Lentiviral vector Manufacturing, Commercial Manufacturing, CDMO, analytical method development, GMP, fill finish, QC/QA release testing, Process Characterization, Regulatory Affairs, Licensing.

 Press Releases

• Andelyn Biosciences and Armatus Bio Partner to Manufacture Suspension-Based (Jan 30, 2024)
  Charcot-Marie-Tooth Type 1A (CMT1A) is a rare neurological disease associated with independence-limiting disability and risk of fatal complications.

• Andelyn Biosciences Selected by Ultragenyx for Late-Stage Process Performan (Jan 30, 2024)
  Andelyn selected by Ultragenyx (NASDAQ: RARE) to perform late-stage Process Performance Qualification manufacturing of the company’s UX111 gene therapy for MPS IIIA.

• Battelle, Andelyn Biosciences, and AmplifyBio Awarded Task Orders for Plasm (Jan 30, 2024)
  Awarded a new task order from the NINDS to manufacture suspension process gene therapy for the transformative treatment of AGU.

• Andelyn Biosciences and The Ohio State University Collaborate for Pre-clini (Jan 30, 2024)
  Andelyn Biosciences, Inc. is collaborating with OSU Gene Therapy Institute for the development and clinical manufacturing of novel gene therapies.
   

• Andelyn Biosciences and Purespring Therapeutics Partner to Manufacture Nove (Jan 30, 2024)
  Andelyn and Purespring Therapeutics to accelerate the manufacture of their gene therapies for the treatment of chronic renal diseases that are currently poorly addressed.